Drug Profile


Alternative Names: COL-144; LY-573144

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator Eli Lilly; Lundbeck A/S
  • Developer CoLucid Pharmaceuticals
  • Class Antimigraines; Benzamides; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Serotonin 1F receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Migraine

Highest Development Phases

  • Phase III Migraine

Most Recent Events

  • 04 Jan 2017 CoLucid Pharmaceuticals, Algorithme Pharma and Cognitive Research Corporation plan a phase I pharmacodynamics trial in Healthy volunteers in USA and Canada (PO, Tablet) (NCT03012334)
  • 30 Dec 2016 CoLucid Pharmaceuticals plans a phase I pharmacokinetics trial in USA and Canada (PO, Tablet) (NCT03009162)
  • 05 Oct 2016 Efficacy data from a phase III SAMURAI trial in Migraine released by CoLucid
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top